Please login to the form below
trametinib
This page shows the latest trametinib news and features for those working in and with pharma, biotech and healthcare.
Half of European cancer drug trials ‘biased’, says BMJ
That included Servier’s leukaemia treatment Oncaspar(pegaspargase), which had five studies deemed to be at risk, while others included Novartis’ Mekinist(trametinib; three studies) and Pfizer’s Ibrance(palbociclib; two
Latest news
-
Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
Proactive adjuvant treatment could extend melanoma patient lives. England’s cost effectiveness watchdog NICE has recommended the use of Novartis’ Tafinlar (dabrafenib and Mekinst (trametinib) combination in melanoma. ... Clinical trial results showed
-
Novartis wins key adjuvant Taf/Mek approval in Europe
The EMA has approved Tafinlar (dabrafenib) and Mekinist (trametinib) for the adjuvant (post-surgery) treatment of stage III melanoma patients with BRAF V600 mutations, following in the footsteps of the US
-
Novartis scores but Roche misses in melanoma trials
The combination of Novartis BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) met its objective with a 53% reduction in death or disease recurrence in the COMBI-AD trial, which ... Both ipilimumab and the combination of
-
Novartis gets lung cancer OK for Tafinlar/Mekinist combo
The European Commission has cleared BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) for patients with advanced or metastatic NSCLC whose tumours bear the BRAF V600 mutation.
-
J&J gets CHMP backing for broader Darzalex use
CHMP round-up. At its meeting last week the CHMP also gave its blessing to the combination of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive non-small cell lung
More from news
Approximately 7 fully matching, plus 33 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Trials resume for AZ/Oxford University COVID-19 vaccine
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
- Roche’s Ocrevus boasts positive long-term data in MS
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Moderna inks R&D agreements with Vertex and Chiesi
PMHub
Wordbird
Wordbird is a healthcare communications agency with creative, compelling copy at its heart....
Latest intelligence
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
- Route 66: can remote working put two-thirds of us back on the road to engaged employment?
- Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Quick links
Infographics
